PA
TERN

Perceptive Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Perceptive Advisors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,075,000
Closed -$9.41M – 103
2023
Q2 		$9.41M Buy
+1,075,000
New +$12.5M 0.27% 67

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Perceptive Advisors's TERN Position: Q1 2024 in Review

Perceptive Advisors sold out of Terns Pharmaceuticals (TERN) in Q1 2024, closing a stake of 1,075,000 shares — an estimated $6.98M sold.

Perceptive Advisors first reported a position in TERN in Q1 2023 and held it in 3 quarters. The position peaked at $16M in Q1 2023. 112 funds tracked by Wall St. Rank hold TERN as of Q1 2024.

  • Perceptive Advisors reported no remaining Terns Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Perceptive Advisors sold 1,075,000 Terns Pharmaceuticals shares in Q1 2024, an estimated $6.98M.
  • Perceptive Advisors first reported a position in Terns Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Perceptive Advisors's Terns Pharmaceuticals position peaked at $16M in Q1 2023.
  • 112 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2024.

Based on Perceptive Advisors's 13F filing for Q1 2024, filed 15 May 2024.